Clinical Trials Directory

Trials / Completed

CompletedNCT00027183

Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa

Role of Exotoxins in the Pathogenesis of Pseudomonas Aeruginosa

Status
Completed
Phase
Study type
Observational
Enrollment
134 (actual)
Sponsor
National Heart, Lung, and Blood Institute (NHLBI) · NIH
Sex
All
Age
9 Years – 99 Years
Healthy volunteers
Not accepted

Summary

Some bacteria that cause disease can produce toxic substances that may worsen the disease. Pseudomonas aeruginosa is a bacteria that can produce a variety of toxins and is of special interest for patients with cystic fibrosis and repeated long term lung infections. The goal of this study is to determine whether specific toxins produced by Pseudomonas aeruginosa may be important in the disease process of chronic lung infections of patients with cystic fibrosis. This study will attempt to measure bacterial production of toxins in blood and sputum and immune system response to toxins in the blood....

Detailed description

The goal of this study is to determine whether virulence determinants that use the type III-secretory pathway may be important in the pathogenesis of chronic Pseudomonas aeruginosa lung infections in patients with cystic fibrosis (CF). The studies will quantify bacterial effector proteins in serum and sputum and the immune response to specific products as reflected by antibodies in serum. Candidate effector proteins include: (1) exotoxin A, a non-type III-dependent ADP-ribosyltransferase and cytotoxin that does not use the Type III secretory pathway, (2) ExoS, a type III pathway-dependent extracellular ADP-ribosyltransferase with cytotoxic activity, (3) ExoU, another type III-dependent cytotoxin, that is responsible for epithelial injury in acute lung infections, and (4) PcrV, a homolog to the V antigen of Yersinia.

Conditions

Timeline

Start date
1998-03-17
Primary completion
2006-09-07
Completion
2018-12-28
First posted
2001-11-28
Last updated
2022-06-06

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00027183. Inclusion in this directory is not an endorsement.